BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35863698)

  • 1. Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines.
    Glykofridis IE; Henneman AA; Balk JA; Goeij-de Haas R; Westland D; Piersma SR; Knol JC; Pham TV; Boekhout M; Zwartkruis FJT; Wolthuis RMF; Jimenez CR
    Mol Cell Proteomics; 2022 Sep; 21(9):100263. PubMed ID: 35863698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
    Hasumi H; Baba M; Hasumi Y; Furuya M; Yao M
    Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.
    Furuya M; Hasumi H; Baba M; Tanaka R; Iribe Y; Onishi T; Nagashima Y; Nakatani Y; Isono Y; Yao M
    Lab Invest; 2017 Mar; 97(3):343-351. PubMed ID: 27991910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression.
    Nagashima K; Fukushima H; Shimizu K; Yamada A; Hidaka M; Hasumi H; Ikebe T; Fukumoto S; Okabe K; Inuzuka H
    Oncotarget; 2017 Feb; 8(6):9947-9960. PubMed ID: 28039480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TFEB and TFE3 drive kidney cystogenesis and tumorigenesis.
    Di Malta C; Zampelli A; Granieri L; Vilardo C; De Cegli R; Cinque L; Nusco E; Pece S; Tosoni D; Sanguedolce F; Sorrentino NC; Merino MJ; Nielsen D; Srinivasan R; Ball MW; Ricketts CJ; Vocke CD; Lang M; Karim B; Lanfrancone L; Schmidt LS; Linehan WM; Ballabio A
    EMBO Mol Med; 2023 May; 15(5):e16877. PubMed ID: 36987696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.
    Schmidt LS
    Fam Cancer; 2013 Sep; 12(3):357-64. PubMed ID: 23108783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome.
    Napolitano G; Di Malta C; Esposito A; de Araujo MEG; Pece S; Bertalot G; Matarese M; Benedetti V; Zampelli A; Stasyk T; Siciliano D; Venuta A; Cesana M; Vilardo C; Nusco E; Monfregola J; Calcagnì A; Di Fiore PP; Huber LA; Ballabio A
    Nature; 2020 Sep; 585(7826):597-602. PubMed ID: 32612235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.
    Tee AR; Pause A
    Fam Cancer; 2013 Sep; 12(3):367-72. PubMed ID: 23096221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLCN, a novel autophagy component, interacts with GABARAP and is regulated by ULK1 phosphorylation.
    Dunlop EA; Seifan S; Claessens T; Behrends C; Kamps MA; Rozycka E; Kemp AJ; Nookala RK; Blenis J; Coull BJ; Murray JT; van Steensel MA; Wilkinson S; Tee AR
    Autophagy; 2014 Oct; 10(10):1749-60. PubMed ID: 25126726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMPK promotes induction of the tumor suppressor FLCN through activation of TFEB independently of mTOR.
    Collodet C; Foretz M; Deak M; Bultot L; Metairon S; Viollet B; Lefebvre G; Raymond F; Parisi A; Civiletto G; Gut P; Descombes P; Sakamoto K
    FASEB J; 2019 Nov; 33(11):12374-12391. PubMed ID: 31404503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
    Lu X; Wei W; Fenton J; Nahorski MS; Rabai E; Reiman A; Seabra L; Nagy Z; Latif F; Maher ER
    Mol Cancer Ther; 2011 Jan; 10(1):80-9. PubMed ID: 21220493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of FLCN inhibits canonical WNT signaling via TFE3.
    Kennedy JC; Khabibullin D; Hougard T; Nijmeh J; Shi W; Henske EP
    Hum Mol Genet; 2019 Oct; 28(19):3270-3281. PubMed ID: 31272105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.
    Hong SB; Oh H; Valera VA; Stull J; Ngo DT; Baba M; Merino MJ; Linehan WM; Schmidt LS
    Mol Cancer; 2010 Jun; 9():160. PubMed ID: 20573232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.
    Houweling AC; Gijezen LM; Jonker MA; van Doorn MB; Oldenburg RA; van Spaendonck-Zwarts KY; Leter EM; van Os TA; van Grieken NC; Jaspars EH; de Jong MM; Bongers EM; Johannesma PC; Postmus PE; van Moorselaar RJ; van Waesberghe JH; Starink TM; van Steensel MA; Gille JJ; Menko FH
    Br J Cancer; 2011 Dec; 105(12):1912-9. PubMed ID: 22146830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E; Laubscher D; Hopfer H; Streit M; Matyas G
    Fam Cancer; 2016 Jan; 15(1):127-32. PubMed ID: 26342594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland.
    Isono Y; Furuya M; Kuwahara T; Sano D; Suzuki K; Jikuya R; Mitome T; Otake S; Kawahara T; Ito Y; Muraoka K; Nakaigawa N; Kimura Y; Baba M; Nagahama K; Takahata H; Saito I; Schmidt LS; Linehan WM; Kodama T; Yao M; Oridate N; Hasumi H
    Biochem Biophys Res Commun; 2020 Feb; 522(4):931-938. PubMed ID: 31806376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique mutation, accelerated mTOR signaling and angiogenesis in the pulmonary cysts of Birt-Hogg-Dubé syndrome.
    Nishii T; Tanabe M; Tanaka R; Matsuzawa T; Okudela K; Nozawa A; Nakatani Y; Furuya M
    Pathol Int; 2013 Jan; 63(1):45-55. PubMed ID: 23356225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLCN-regulated miRNAs suppressed reparative response in cells and pulmonary lesions of Birt-Hogg-Dubé syndrome.
    Min H; Ma D; Zou W; Wu Y; Ding Y; Zhu C; Lin A; Song S; Liang Q; Chen B; Zhang B; Wan Y; Ye M; Pan Y; Wen Y; Yi L; Gao Q
    Thorax; 2020 Jun; 75(6):476-485. PubMed ID: 32184379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Neoplasms in Patients with Birt-Hogg-Dubé Syndrome: Histopathological Features and Genetic and Somatic Events.
    Furuya M; Tanaka R; Okudela K; Nakamura S; Yoshioka H; Tsuzuki T; Shibuya R; Yatera K; Shirasaki H; Sudo Y; Kimura N; Yamada K; Uematsu S; Kunimura T; Kato I; Nakatani Y
    PLoS One; 2016; 11(3):e0151476. PubMed ID: 26974543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.